PMC4899579_01
Liver enzyme progression for individual patients. EOT: end of treatment; ALP: alkaline phosphatase.
CRIID2016-6151570.001.jpg
PMC4899579_04_CRIID2016-6151570.001.jpg
fig1
At week 2, safety labs revealed unchanged AST/ALT values and a slight increase in total bilirubin (Figure 1(d)), as well as a decline in hemoglobin and hematocrit from 15.3/45.2 g/L to 13.5/38.3 g/L, respectively. By week 4 of treatment, AST/ALT had increased while total bilirubin remained stable (Figure 1(d)) and he reported mild foot swelling, not present prior to treatment initiation. By week 7 of treatment, AST/ALT had increased further (Figure 1(d)), hemoglobin and hematocrit remained stable, and creatinine had increased from 1.34 at baseline to 2.15 mg/dL. HCV therapy (week 3 of ledipasvir-sofosbuvir) serum creatinine and AST/ALT had returned to baseline and remained normal thereafter (Figure 1(d)). He completed a total of 8 weeks of ledipasvir-sofosbuvir following the 7 weeks of PrOD and ribavirin.
PMC4899579_02
Liver enzyme progression for individual patients. EOT: end of treatment; ALP: alkaline phosphatase.
CRIID2016-6151570.001.jpg
PMC4899579_04_CRIID2016-6151570.001.jpg
fig1
At week 2, safety labs revealed unchanged AST/ALT values and a slight increase in total bilirubin (Figure 1(d)), as well as a decline in hemoglobin and hematocrit from 15.3/45.2 g/L to 13.5/38.3 g/L, respectively. By week 4 of treatment, AST/ALT had increased while total bilirubin remained stable (Figure 1(d)) and he reported mild foot swelling, not present prior to treatment initiation. By week 7 of treatment, AST/ALT had increased further (Figure 1(d)), hemoglobin and hematocrit remained stable, and creatinine had increased from 1.34 at baseline to 2.15 mg/dL. HCV therapy (week 3 of ledipasvir-sofosbuvir) serum creatinine and AST/ALT had returned to baseline and remained normal thereafter (Figure 1(d)). He completed a total of 8 weeks of ledipasvir-sofosbuvir following the 7 weeks of PrOD and ribavirin.
PMC4899579_03
Liver enzyme progression for individual patients. EOT: end of treatment; ALP: alkaline phosphatase.
CRIID2016-6151570.001.jpg
PMC4899579_04_CRIID2016-6151570.001.jpg
fig1
At week 2, safety labs revealed unchanged AST/ALT values and a slight increase in total bilirubin (Figure 1(d)), as well as a decline in hemoglobin and hematocrit from 15.3/45.2 g/L to 13.5/38.3 g/L, respectively. By week 4 of treatment, AST/ALT had increased while total bilirubin remained stable (Figure 1(d)) and he reported mild foot swelling, not present prior to treatment initiation. By week 7 of treatment, AST/ALT had increased further (Figure 1(d)), hemoglobin and hematocrit remained stable, and creatinine had increased from 1.34 at baseline to 2.15 mg/dL. HCV therapy (week 3 of ledipasvir-sofosbuvir) serum creatinine and AST/ALT had returned to baseline and remained normal thereafter (Figure 1(d)). He completed a total of 8 weeks of ledipasvir-sofosbuvir following the 7 weeks of PrOD and ribavirin.
PMC4899579_04
Liver enzyme progression for individual patients. EOT: end of treatment; ALP: alkaline phosphatase.
CRIID2016-6151570.001.jpg
PMC4899579_04_CRIID2016-6151570.001.jpg
fig1
At week 2, safety labs revealed unchanged AST/ALT values and a slight increase in total bilirubin (Figure 1(d)), as well as a decline in hemoglobin and hematocrit from 15.3/45.2 g/L to 13.5/38.3 g/L, respectively. By week 4 of treatment, AST/ALT had increased while total bilirubin remained stable (Figure 1(d)) and he reported mild foot swelling, not present prior to treatment initiation. By week 7 of treatment, AST/ALT had increased further (Figure 1(d)), hemoglobin and hematocrit remained stable, and creatinine had increased from 1.34 at baseline to 2.15 mg/dL. HCV therapy (week 3 of ledipasvir-sofosbuvir) serum creatinine and AST/ALT had returned to baseline and remained normal thereafter (Figure 1(d)). He completed a total of 8 weeks of ledipasvir-sofosbuvir following the 7 weeks of PrOD and ribavirin.